Video
Dr. Spigel on FDA Approval of Pembrolizumab/Chemo Combo in NSCLC
Author(s):
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non–small cell lung cancer (NSCLC).
David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the FDA approval of pembrolizumab plus chemotherapy as a frontline treatment for patients with non—small cell lung cancer (NSCLC).
Latest CME
View All
Video
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Apr 23rd 2025 - Apr 24th 2026
online-activity
Video
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Apr 23rd 2025 - Apr 24th 2026
online-activity
Video
Addressing Unmet Needs in HER2+ Metastatic BTC
Apr 18th 2025 - Apr 19th 2026
online-activity
Related Content
.png?fit=crop&auto=format)
